patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_929640 | REC_0005901 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 3.3 | 74 | female | 2 | 17 | 5 | 1 | sotorasib 960 mg daily | 19.6 | false | MSS | 2026-03-15T05:35:58.304345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390265 | REC_0005902 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 13.9 | 65 | female | 0 | 20 | 6.3 | 6 | osimertinib 80 mg daily | 5.7 | false | MSI-H | 2026-03-15T05:35:58.304582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773543 | REC_0005903 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 14.2 | 61 | male | 1 | 8 | 6.9 | 5 | alectinib 600 mg BID | 9.2 | false | MSI-H | 2026-03-15T05:35:58.304864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106715 | REC_0005904 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.1 | 66 | female | 0 | 19 | 6.4 | 1 | osimertinib 80 mg daily | 23.5 | false | MSS | 2026-03-15T05:35:58.305103+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408859 | REC_0005905 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 19 | 14.2 | 75 | female | 0 | 11 | 3.9 | 0 | entrectinib 600 mg daily | 47.8 | false | MSS | 2026-03-15T05:35:58.305348+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725011 | REC_0005906 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 7.3 | 60 | female | 0 | 14 | 5.8 | 2 | osimertinib 80 mg daily | 15.9 | false | MSS | 2026-03-15T05:35:58.305594+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844045 | REC_0005907 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 6.1 | 60 | male | 0 | 11 | 5.5 | 4 | alectinib 600 mg BID | 8.1 | true | MSS | 2026-03-15T05:35:58.305843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178089 | REC_0005908 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 14.2 | 71 | female | 0 | 16 | 5.7 | 5 | osimertinib 80 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:35:58.306091+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538489 | REC_0005909 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 13.5 | 58 | female | 1 | 17 | 4.4 | 1 | pembrolizumab 200 mg q3w | 16.3 | true | MSS | 2026-03-15T05:35:58.306347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887326 | REC_0005910 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 5.8 | 51 | male | 0 | 68 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.2 | true | MSS | 2026-03-15T05:35:58.306605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537700 | REC_0005911 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 7 | 68 | female | 0 | 16 | 6.6 | 6 | pembrolizumab 200 mg q3w | 7.3 | false | MSS | 2026-03-15T05:35:58.306864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320242 | REC_0005912 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.8 | 74 | female | 3 | 18 | 6.7 | 7 | alectinib 600 mg BID | 5.2 | false | MSS | 2026-03-15T05:35:58.307115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373269 | REC_0005913 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 11.4 | 52 | female | 0 | 6 | 3.5 | 6 | osimertinib 80 mg daily | 10.7 | true | MSI-H | 2026-03-15T05:35:58.307357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760982 | REC_0005914 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.1 | 82 | male | 2 | 48 | 6.4 | 6 | pembrolizumab 200 mg q3w | 9 | false | MSS | 2026-03-15T05:35:58.307592+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445669 | REC_0005915 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 8.1 | 58 | female | 1 | 14 | 8 | 2 | sotorasib 960 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:58.307826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_273859 | REC_0005916 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 12.3 | 67 | female | 0 | 16 | 5.5 | 6 | entrectinib 600 mg daily | 5.2 | false | MSS | 2026-03-15T05:35:58.308267+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854910 | REC_0005917 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 5.6 | 58 | female | 0 | 55 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.8 | false | MSS | 2026-03-15T05:35:58.308514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704965 | REC_0005918 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 11.2 | 69 | female | 1 | 19 | 6 | 2 | osimertinib 80 mg daily | 27.1 | true | MSI-H | 2026-03-15T05:35:58.308757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754175 | REC_0005919 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 9.8 | 61 | male | 1 | 57 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.1 | false | MSS | 2026-03-15T05:35:58.308996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826343 | REC_0005920 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11.8 | 69 | female | 1 | 0 | 6.4 | 5 | entrectinib 600 mg daily | 17 | false | MSI-H | 2026-03-15T05:35:58.309226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609710 | REC_0005921 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 7.8 | 66 | female | 1 | 15 | 3.9 | 6 | osimertinib 80 mg daily | 4.8 | false | MSS | 2026-03-15T05:35:58.309453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452280 | REC_0005922 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.6 | 64 | female | 0 | 11 | 4.2 | 6 | alectinib 600 mg BID | 12.2 | true | MSS | 2026-03-15T05:35:58.309688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_118440 | REC_0005923 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 15 | 12.3 | 50 | female | 0 | 24 | 6 | 1 | alectinib 600 mg BID | 25.3 | false | MSI-H | 2026-03-15T05:35:58.309922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528455 | REC_0005924 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 9.6 | 74 | male | 2 | 11 | 4.3 | 5 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.310155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826171 | REC_0005925 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 8 | 68 | male | 0 | 80 | 7.8 | 3 | carboplatin + paclitaxel + pembrolizumab | 9.4 | true | MSS | 2026-03-15T05:35:58.310387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_565847 | REC_0005926 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 29 | 8 | 63 | male | 0 | 64 | 6.2 | 0 | pembrolizumab 200 mg q3w | 64.3 | true | MSS | 2026-03-15T05:35:58.310619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192935 | REC_0005927 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 35 | 10.6 | 68 | male | 0 | 22 | 3.9 | 1 | osimertinib 80 mg daily | 7.8 | true | MSI-H | 2026-03-15T05:35:58.310856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156310 | REC_0005928 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 6.9 | 75 | male | 1 | 78 | 6.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.3 | true | MSS | 2026-03-15T05:35:58.311087+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543465 | REC_0005929 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 11.1 | 71 | male | 1 | 9 | 6 | 2 | osimertinib 80 mg daily | 36.3 | false | MSI-H | 2026-03-15T05:35:58.311383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_471340 | REC_0005930 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 16 | 7.2 | 66 | female | 0 | 39 | 4 | 5 | pembrolizumab 200 mg q3w | 8.2 | true | MSS | 2026-03-15T05:35:58.311614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_163028 | REC_0005931 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 13.1 | 64 | female | 1 | 16 | 6.9 | 1 | alectinib 600 mg BID | 18.2 | false | MSI-H | 2026-03-15T05:35:58.311853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947432 | REC_0005932 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 10.7 | 78 | female | 2 | 24 | 4.4 | 6 | osimertinib 80 mg daily | 6 | false | MSS | 2026-03-15T05:35:58.312176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404251 | REC_0005933 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 9.5 | 75 | female | 2 | 10 | 6 | 9 | sotorasib 960 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:58.312417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385632 | REC_0005934 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 16.5 | 69 | female | 1 | 21 | 4.3 | 1 | osimertinib 80 mg daily | 14.2 | false | MSI-H | 2026-03-15T05:35:58.312650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704805 | REC_0005935 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 14.1 | 78 | female | 2 | 12 | 5.9 | 7 | alectinib 600 mg BID | 4 | true | MSI-H | 2026-03-15T05:35:58.312882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366657 | REC_0005936 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 10.1 | 90 | male | 2 | 64 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.8 | false | MSS | 2026-03-15T05:35:58.313114+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253531 | REC_0005937 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 12.3 | 73 | female | 1 | 10 | 5.1 | 5 | entrectinib 600 mg daily | 12.7 | true | MSS | 2026-03-15T05:35:58.313352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969655 | REC_0005938 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 4.7 | 63 | female | 1 | 37 | 7.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.7 | false | MSS | 2026-03-15T05:35:58.313584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254279 | REC_0005939 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 6.2 | 62 | male | 0 | 17 | 5 | 5 | osimertinib 80 mg daily | 14.8 | false | MSS | 2026-03-15T05:35:58.313816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858621 | REC_0005940 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 11 | 85 | female | 1 | 7 | 4.4 | 3 | alectinib 600 mg BID | 5.7 | true | MSS | 2026-03-15T05:35:58.314046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185380 | REC_0005941 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.8 | 79 | female | 1 | 23 | 5 | 6 | osimertinib 80 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:35:58.314279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823211 | REC_0005942 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 16 | 71 | male | 1 | 20 | 5.4 | 7 | pembrolizumab 200 mg q3w | 13.3 | true | MSS | 2026-03-15T05:35:58.314579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_621466 | REC_0005943 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 7.8 | 88 | female | 1 | 18 | 4.8 | 3 | osimertinib 80 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:58.314810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711961 | REC_0005944 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.8 | 67 | female | 0 | 61 | 3.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.8 | false | MSS | 2026-03-15T05:35:58.315045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267256 | REC_0005945 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 14.4 | 66 | male | 1 | 21 | 6.8 | 2 | osimertinib 80 mg daily | 20.1 | true | MSS | 2026-03-15T05:35:58.315284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862442 | REC_0005946 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 28 | 5 | 70 | female | 2 | 21 | 2 | 0 | pembrolizumab 200 mg q3w | 35.4 | false | MSS | 2026-03-15T05:35:58.315511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420147 | REC_0005947 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11.3 | 70 | male | 1 | 11 | 6.5 | 6 | entrectinib 600 mg daily | 17.9 | false | MSI-H | 2026-03-15T05:35:58.315746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947213 | REC_0005948 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 4.6 | 72 | male | 2 | 18 | 4.2 | 1 | sotorasib 960 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:58.315979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493625 | REC_0005949 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 16 | 9.3 | 73 | female | 2 | 11 | 5.3 | 0 | alectinib 600 mg BID | 42.2 | false | MSS | 2026-03-15T05:35:58.316270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570904 | REC_0005950 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 14 | 9.4 | 70 | male | 2 | 21 | 6 | 3 | osimertinib 80 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:58.316517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876443 | REC_0005951 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.6 | 72 | female | 0 | 45 | 5.8 | 3 | carboplatin + paclitaxel + pembrolizumab | 9.6 | false | MSS | 2026-03-15T05:35:58.316773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592372 | REC_0005952 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 3.1 | 79 | female | 2 | 15 | 5.7 | 2 | pembrolizumab 200 mg q3w | 30.7 | true | MSS | 2026-03-15T05:35:58.317011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968266 | REC_0005953 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 17.7 | 79 | female | 1 | 17 | 4.9 | 7 | osimertinib 80 mg daily | 9.3 | false | MSI-H | 2026-03-15T05:35:58.317247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989343 | REC_0005954 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 9.4 | 69 | female | 1 | 22 | 5.5 | 1 | osimertinib 80 mg daily | 28.6 | true | MSS | 2026-03-15T05:35:58.317479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660481 | REC_0005955 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.9 | 71 | male | 3 | 13 | 6.3 | 2 | entrectinib 600 mg daily | 6 | false | MSI-H | 2026-03-15T05:35:58.317798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939388 | REC_0005956 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 1.5 | 82 | female | 2 | 51 | 5.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 25.8 | false | MSS | 2026-03-15T05:35:58.318033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685434 | REC_0005957 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 15 | 46 | male | 0 | 11 | 5.5 | 7 | pembrolizumab 200 mg q3w | 4 | false | MSI-H | 2026-03-15T05:35:58.318272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744759 | REC_0005958 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 14.4 | 75 | female | 1 | 7 | 4.9 | 1 | alectinib 600 mg BID | 23.7 | false | MSS | 2026-03-15T05:35:58.318508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573625 | REC_0005959 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 7 | 61 | female | 1 | 56 | 4.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:58.318744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236322 | REC_0005960 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 18.5 | 73 | female | 1 | 17 | 6.4 | 1 | entrectinib 600 mg daily | 19.5 | false | MSI-H | 2026-03-15T05:35:58.318975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406678 | REC_0005961 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 8.8 | 56 | male | 1 | 6 | 6.9 | 5 | entrectinib 600 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:58.319209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146772 | REC_0005962 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 6.3 | 62 | female | 1 | 14 | 6.2 | 7 | osimertinib 80 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:58.319439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614612 | REC_0005963 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 17.1 | 69 | female | 0 | 12 | 7 | 2 | entrectinib 600 mg daily | 22.8 | false | MSS | 2026-03-15T05:35:58.319672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923809 | REC_0005964 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 22 | 11.4 | 59 | female | 0 | 7 | 5 | 0 | osimertinib 80 mg daily | 42.3 | false | MSI-H | 2026-03-15T05:35:58.319906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631307 | REC_0005965 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 11.9 | 74 | female | 2 | 1 | 5.5 | 9 | alectinib 600 mg BID | 13.1 | true | MSS | 2026-03-15T05:35:58.320180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511268 | REC_0005966 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 11.3 | 62 | male | 0 | 11 | 7.7 | 8 | alectinib 600 mg BID | 11.9 | false | MSI-H | 2026-03-15T05:35:58.320426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866122 | REC_0005967 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 18.6 | 75 | female | 2 | 12 | 4.9 | 2 | sotorasib 960 mg daily | 22.8 | false | MSI-H | 2026-03-15T05:35:58.320662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829282 | REC_0005968 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 34 | 11.9 | 59 | female | 1 | 16 | 5.7 | 6 | entrectinib 600 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:58.320989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784166 | REC_0005969 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 10 | 53 | male | 0 | 24 | 5.9 | 2 | pembrolizumab 200 mg q3w | 22.2 | true | MSS | 2026-03-15T05:35:58.321233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116113 | REC_0005970 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 9.3 | 72 | female | 2 | 18 | 6 | 7 | pembrolizumab 200 mg q3w | 10.1 | true | MSS | 2026-03-15T05:35:58.321466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180105 | REC_0005971 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 6.7 | 61 | male | 0 | 43 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.2 | false | MSS | 2026-03-15T05:35:58.321698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322492 | REC_0005972 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 3.2 | 73 | female | 2 | 16 | 4.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.1 | false | MSS | 2026-03-15T05:35:58.321926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438821 | REC_0005973 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 10.4 | 68 | female | 0 | 18 | 6.6 | 0 | osimertinib 80 mg daily | 29.4 | true | MSS | 2026-03-15T05:35:58.322159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721362 | REC_0005974 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 13.7 | 70 | female | 1 | 18 | 4.9 | 8 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:58.322390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761737 | REC_0005975 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 15 | 57 | male | 1 | 16 | 6 | 2 | osimertinib 80 mg daily | 33.1 | false | MSI-H | 2026-03-15T05:35:58.322627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691704 | REC_0005976 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 16 | 14.7 | 58 | male | 0 | 17 | 4.4 | 2 | osimertinib 80 mg daily | 18.9 | false | MSI-H | 2026-03-15T05:35:58.322860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258862 | REC_0005977 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 5.1 | 80 | female | 2 | 23 | 4.5 | 1 | pembrolizumab 200 mg q3w | 26.1 | false | MSS | 2026-03-15T05:35:58.323092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567513 | REC_0005978 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 7 | 72 | female | 1 | 65 | 6.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.1 | false | MSS | 2026-03-15T05:35:58.323323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730283 | REC_0005979 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 15.1 | 59 | male | 0 | 10 | 5.8 | 3 | alectinib 600 mg BID | 17.6 | true | MSS | 2026-03-15T05:35:58.323559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244944 | REC_0005980 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 9.2 | 61 | female | 0 | 25 | 4.5 | 5 | entrectinib 600 mg daily | 14.7 | false | MSS | 2026-03-15T05:35:58.323792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213496 | REC_0005981 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 16 | 64 | female | 0 | 9 | 6.7 | 3 | pembrolizumab 200 mg q3w | 14.8 | false | MSI-H | 2026-03-15T05:35:58.324119+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717959 | REC_0005982 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 15.1 | 70 | female | 2 | 24 | 6.1 | 4 | pembrolizumab 200 mg q3w | 15.4 | true | MSS | 2026-03-15T05:35:58.324359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191319 | REC_0005983 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 9.4 | 57 | female | 0 | 12 | 3.8 | 6 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.324593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627787 | REC_0005984 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4 | 70 | female | 1 | 33 | 4.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 5.7 | false | MSS | 2026-03-15T05:35:58.324820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581253 | REC_0005985 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 18 | 70 | female | 1 | 16 | 5.2 | 1 | entrectinib 600 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:58.325051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957210 | REC_0005986 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 22 | 11.6 | 61 | male | 1 | 13 | 5.6 | 0 | entrectinib 600 mg daily | 35.4 | true | MSI-H | 2026-03-15T05:35:58.325287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456232 | REC_0005987 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 6.2 | 65 | male | 1 | 14 | 4.6 | 7 | osimertinib 80 mg daily | 7.1 | false | MSS | 2026-03-15T05:35:58.325519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859374 | REC_0005988 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 12.8 | 59 | male | 1 | 11 | 5.8 | 1 | alectinib 600 mg BID | 12.3 | false | MSS | 2026-03-15T05:35:58.325755+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943636 | REC_0005989 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 14.7 | 54 | male | 0 | 32 | 7.2 | 2 | entrectinib 600 mg daily | 17.4 | true | MSS | 2026-03-15T05:35:58.325995+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406173 | REC_0005990 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 12.1 | 84 | female | 1 | 14 | 5 | 0 | osimertinib 80 mg daily | 17.7 | false | MSI-H | 2026-03-15T05:35:58.326226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849737 | REC_0005991 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 10.7 | 67 | female | 1 | 11 | 5.7 | 9 | sotorasib 960 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:35:58.326457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227787 | REC_0005992 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 8.2 | 69 | male | 1 | 23 | 2.6 | 5 | pembrolizumab 200 mg q3w | 4.3 | true | MSS | 2026-03-15T05:35:58.326692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228847 | REC_0005993 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 14.9 | 57 | female | 0 | 16 | 7.5 | 7 | entrectinib 600 mg daily | 16 | false | MSI-H | 2026-03-15T05:35:58.326929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303172 | REC_0005994 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 10.3 | 69 | female | 1 | 18 | 4.2 | 2 | osimertinib 80 mg daily | 18.2 | false | MSI-H | 2026-03-15T05:35:58.327214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332622 | REC_0005995 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 17.9 | 77 | female | 1 | 11 | 6.4 | 5 | alectinib 600 mg BID | 12.5 | true | MSI-H | 2026-03-15T05:35:58.327450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831370 | REC_0005996 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 5.5 | 67 | male | 0 | 24 | 4.4 | 8 | carboplatin + paclitaxel + pembrolizumab | 13.3 | true | MSS | 2026-03-15T05:35:58.327682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812545 | REC_0005997 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 9.2 | 65 | female | 1 | 32 | 4.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.6 | false | MSS | 2026-03-15T05:35:58.327915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_424429 | REC_0005998 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 25 | 17.8 | 73 | female | 2 | 0 | 8.1 | 0 | pembrolizumab 200 mg q3w | 40 | false | MSI-H | 2026-03-15T05:35:58.328328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681756 | REC_0005999 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 9.7 | 58 | female | 0 | 19 | 6.7 | 2 | sotorasib 960 mg daily | 26.4 | false | MSS | 2026-03-15T05:35:58.328571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377434 | REC_0006000 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 15.2 | 60 | male | 0 | 8 | 4.8 | 3 | entrectinib 600 mg daily | 23.3 | false | MSI-H | 2026-03-15T05:35:58.328822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.